Thema: Diabetes mellitus en infectieziekten Het ... - NVMM

ulins inhibits the molecular recognition system of theantibodies. It is important to use tissue cultures insteadof superficial wound swabs to identify causing microorganisms.Recently published guidelines and reviews by theIWGDF and the IDSA have suggested antibiotics for usein diabetic foot infections.Referenties1. International Diabetes Federation. Diabetes atlas. Fifth edition 2011.Available at: http://www.idf.org/diabetesatlas/5e/the-global-burden.2. Ndip A, Lavery LA, Lafontaine J, et al. High levels of foot ulceration andamputation risk in a multiracial cohort of diabetic patients on dialysistherapy Diabetes Care. 2010;33(4): 878-80.3. Verhoeven S, van Ballegooie E, Casparie AF. Impact of late complicationsin type 2 diabetes in a dutch population. Diabet Med. 1991;8(5):435-8.4. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ. Diabeticfoot syndrome: Evaluating the prevalence and incidence of foot pathologyin mexican americans and non-hispanic whites from a diabetes diseasemanagement cohort. Diabetes Care. 2003;26(5):1435-8.5. Ragnarson Tennvall G, Apelqvist J, Eneroth M. Costs of deep footinfections in patients with diabetes mellitus. Pharmacoeconomics.2000;18(3):225-38.6. Shah BR, Hux JE. Quantifying the risk of infectious diseases for peoplewith diabetes. Diabetes Care. 2003;26(2):510-3.7. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infectionsin patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis.2005;41(3):281-8.8. Kim SH, Park KW, Kim YS, et al. Effects of acute hyperglycemia onendothelium-dependent vasodilation in patients with diabetes mellitusor impaired glucose metabolism. Endothelium, 2003;10(2):65-70.9. Bergamaschini L, Gardinali M, Poli M, Lorini R, Bosi E, Agostoni A.Complement activation in diabetes mellitus. J Clin Lab Immunol.1991;35(3):121-7.10. Saiepour D, Sehlin J, Oldenborg PA. Insulin inhibits phagocytosis innormal human neutrophils via PKCalpha/beta-dependent priming ofF-actin assembly. Inflamm Res. 2006;55(3):85-91.11. Turina M, Fry DE, Polk HC,Jr. Acute hyperglycemia and the innateimmune system: Clinical, cellular, and molecular aspects. Crit Care Med.2005;33(7):1624-33.12. Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H,Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med.1997;14(1):29-34.13. Walrand S, Guillet C, Boirie Y, Vasson MP. In vivo evidences that insulinregulates human polymorphonuclear neutrophil functions. J Leukoc Biol.2004;76(6):1104-10.14. Collison KS, Parhar RS, Saleh SS, et al. RAGE-mediated neutrophildysfunction is evoked by advanced glycation end products (AGEs). JLeukoc Biol. 2002;71(3):433-44.15. Geerlings SE, Hoepelman AI. Immune dysfunction in patientswith diabetes mellitus (DM). FEMS Immunol Med Microbiol.1999;26(3-4):259-65.16. Cavalot F, Anfossi G, Russo I, et al. Insulin, at physiological concentrations,enhances the polymorphonuclear leukocyte chemotacticproperties. Horm Metab Res. 1992;24(5):225-8.17. Perner A, Nielsen SE, Rask-Madsen J. High glucose impairs superoxideproduction from isolated blood neutrophils. Intensive Care Med.2003;29(4):642-5.19. Peters EJ, Lipsky BA, Berendt AR, et al. A systematic review of the effectivenessof interventions in the management of infection in the diabeticfoot Diabetes Metab Res Rev. 2012;28 Suppl 1:142-62.20. Eibl N, Spatz M, Fischer GF, et al. Impaired primary immune responsein type-1 diabetes: Results from a controlled vaccination study. ClinImmunol. 2002;103(3):249-59.21. Spatz M, Eibl N, Hink S, et al. Impaired primary immune response intype-1 diabetes. functional impairment at the level of APCs and T-cells.Cell Immunol. 2003;221(1):15-26.22. Diepersloot RJ, Bouter KP, van BR, Lucas CJ, Masurel N, Erkelens DW.Cytotoxic T-cell response to influenza A subunit vaccine in patients withtype 1 diabetes mellitus. Neth J Med. 1989;35(1-2):68-75.23. el-Madhun AS, Cox RJ, Seime A, Sovik O, Haaheim LR. Systemic andlocal immune responses after parenteral influenza vaccination in juvenilediabetic patients and healthy controls: Results from a pilot study. Vaccine.1998;16(0264-410;2-3):156-60.24. Marseglia G, Alibrandi A, d’Annunzio G, et al. Long term persistence ofanti-HBs protective levels in young patients with type 1 diabetes afterrecombinant hepatitis B vaccine. Vaccine. 2000;19(0264-410;7-8):680-3.25. Lapolla A, Tonani R, Fedele D, et al. Non-enzymatic glycation of IgG: Anin vivo study. Horm Metab Res. 2002;34(5):260-4.26. Meiland R, Geerlings SE, De Neeling AJ, Hoepelman AI. Diabetes mellitusin itself is not a risk factor for antibiotic resistance in escherichia coliisolated from patients with bacteriuria Diabet Med. 2004;21(9):1032-4.27. Mutluoglu M, Uzun G, Turhan V, Gorenek L, Ay H, Lipsky BA. Howreliable are cultures of specimens from superficial swabs compared withthose of deep tissue in patients with diabetic foot ulcers? J DiabetesComplications. 2012.28. Senneville E, Melliez H, Beltrand E, et al. Culture of percutaneousbone biopsy specimens for diagnosis of diabetic foot osteomyelitis:Concordance with ulcer swab cultures. Clin Infect Dis. 2006;42(1):57-62.29. Senneville E, Lombart A, Beltrand E, et al. Outcome of diabetic foot osteomyelitistreated nonsurgically: A retrospective cohort study. DiabetesCare. 2008;31(4):637-42.30. Senneville E, Yazdanpanah Y, Cazaubiel M, et al. Rifampicin-ofloxacin oralregimen for the treatment of mild to moderate diabetic foot osteomyelitis.J Antimicrob Chemother. 2001;48(6):927-30.31. Bus SA, Valk GD, van Deursen RW, et al. The effectiveness of footwearand offloading interventions to prevent and heal foot ulcers and reduceplantar pressure in diabetes: A systematic review. Diabetes Metab ResRev. 2008;24 Suppl 1:S162-80.32. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 infectious diseases societyof america clinical practice guideline for the diagnosis and treatment ofdiabetic foot infections Clin Infect Dis. 2012;54(12):e132-73.33. Lipsky BA, Peters EJ, Berendt AR, et al. Specific guidelines for thetreatment of diabetic foot infections 2011 Diabetes Metab Res Rev.2012;28 Suppl 1: 234-5.34. Lipsky BA, Peters EJ, Senneville E, et al. Expert opinion on themanagement of infections in the diabetic foot Diabetes Metab Res Rev.2012;28 Suppl 1: 163-78.35. Clinical Guidelines Task Force. Guide for guidelines. A guide for clinicalguideline development. Vol. www.idf.org. Brussels, Belgium: InternationalDiabetes Federation, 2003.36. Bakker K, Apelqvist J, Schaper NC, International Working Group onDiabetic Foot Editorial Board. Practical guidelines on the managementand prevention of the diabetic foot 2011 Diabetes Metab Res Rev, 2012;28Suppl 1: 225-31.37. International Working Group on the Diabetic Foot. Internationalconsensus on the diabetic foot and supplements, DVD. 2011;CompleteIWGDF data DVD Guidelines 2011 at http://shop.idf.org.18. Cruciani M, Lipsky BA, Mengoli C, de LF. Are granulocyte colony-stimulatingfactors beneficial in treating diabetic foot infections?: A metaanalysis.Diabetes Care. 2005;28(2):454-60.Ned Tijdschr Med Microbiol 2012;20:nr4162